Article
Stepwise KPC mutational accumulation confers high-level ceftazidime-avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Sept 2026
Huang Haijun, Zhou Longjie, Xu Haotian, Liu Qianhao, Wang Linfang, Han Xinhong, He Jintao, Zhou Hua
Abstract excerpt
Ceftazidime-avibactam (CZA) has become an effective therapeutic option against carbapenem-resistant Klebsiella pneumoniae (CRKP). The emergence of Klebsiella pneumoniae carbapenemase (KPC) variants in CRKP is a major cause of CZA resistance. However, high-level CZA resistance conferred by accumulated KPC mutations was seldom reported. In this study, we observed that high-level ceftazidime-avibactam resistance was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
